<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00154050</url>
  </required_header>
  <id_info>
    <org_study_id>IKPD KARDCHEM 02-04</org_study_id>
    <nct_id>NCT00154050</nct_id>
  </id_info>
  <brief_title>High Dose Candesartan Versus Quinapril for Restenosis Prophylaxis After Stent Angioplasty</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <brief_summary>
    <textblock>
      The study is designed to test the hypothesis that high dose candesartan treatment compared to
      quinapril is able to reduce intima hyperproliferation and the restenosis rate after stent
      angioplasty in peripheral occlusive artery disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are randomly assigned to treatment with either candesartan 32 mg/d or Quinapril 20
      mg/d before the angioplasty. Walking distance, intima media thickness and crurobrachial
      pressure ratios are compared after 6 weeks, 3 months and 6 months. After 6 months an
      angiographic control is performed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date>July 2006</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Restenosis/reintervention after 6 months</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>pain-free walking distance</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>crurobrachial pressure ratios</measure>
  </secondary_outcome>
  <enrollment>22</enrollment>
  <condition>Arterial Occlusive Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>candesartan (drug) or quinapril (drug)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male and female

          -  peripheral occlusive arterial disease Stad IIb Fontaine classification

        Exclusion Criteria:

          -  patients with lesions not available for PTA

          -  renal insufficiency

          -  patients on calcium-antagonists
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilhelm Kirch, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institute of Clinical Pharmacology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chemnitz Hospital, Dept. of Internal Medicine I</name>
      <address>
        <city>Chemnitz</city>
        <zip>09313</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>September 11, 2006</last_update_submitted>
  <last_update_submitted_qc>September 11, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2006</last_update_posted>
  <keyword>restenosis</keyword>
  <keyword>intima hyperproliferation</keyword>
  <keyword>stent angioplasty</keyword>
  <keyword>pain-free walking distance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Quinapril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

